Navigation Links
US Oncology Named to FORTUNE Magazine's Most Admired Companies List for Third Time
Date:3/12/2009

HOUSTON, March 12 /PRNewswire/ -- US Oncology, Inc., one of the nation's largest cancer care services companies, has been named to FORTUNE magazine's Most Admired Companies list for 2009. The company ranks third in the Health Care: Pharmacy and Other category. This is the third time US Oncology has been honored with FORTUNE magazine's Most Admired Companies distinction, having been named to the list in 2004 and 2007 in the Diversified Outsourcing Services category.

The magazine's annual list is considered the definitive report card on corporate reputations. Ranked by top industry executives and financial analysts on nine areas of leadership, US Oncology placed third in its sector in the categories of:

  • Innovation
  • People management
  • Use of corporate assets
  • Social responsibility
  • Quality of product/services

The company ranks in the top five of all nine categories, including quality of management, financial soundness (ranked 4), long-term investment and global competitiveness (ranked 5).

US Oncology collaborates with providers, payers, biotech/pharmaceutical and medical equipment manufacturers to increase patient access to advanced cancer care. Recent innovation at US Oncology includes:

  • Innovent Oncology and Level I Pathways: payers and providers working together to give patients the highest quality care possible at more predictable costs. Using evidence-based treatment guidelines, disease management, and advanced care planning, the programs reduce treatment variability, contain costs and improve patient outcomes
  • Oncology Portal: web portal where oncology physicians can engage in virtual tumor boards, share information, stay current on the latest innovations and gain access to the most up-to-date clinical information and resources
  • PatientRM: award-winning patient-centric case management software that improves patient safety, and collects, manages and analyzes data on thousands of like and unlike patient cases from across the nation
  • Quality and efficiency procedures: using elements of lean six sigma, US Oncology helps practices enhance patient safety, accuracy of medical records, and the overall patient experience
  • iKnowMed expansion: more than 700,000 patients can now be served through this oncology-specific electronic medical records system (EMR) offering clinical decision support to facilitate evidence-based medicine and patient safety

Over the past few years, US Oncology has expanded its existing robust clinical trials capabilities with additional services that help biotech/pharmaceutical and medical equipment manufacturers bring new therapies to patients faster. In 2008, US Oncology affiliated practices began enrolling patients in trials with Radiation Therapy Oncology Group (RTOG), and less than one year later was named as one of the top accruing members.

US Oncology also offers customized clinical development services through its full-service clinical research organization (CRO) as well as innovative solutions through its personalized research organization (PRO). Last year, more than 3,400 patients receiving treatment through the US Oncology network were enrolled in clinical research trials across the nation. These services, as well as many others, are offered as an integrated solutions concept that serves the best interests of patients, practices and biotech/pharmaceutical partners.

About US Oncology

US Oncology, headquartered in the Houston area, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to treatment and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,211 physicians operating in 456 locations, including 94 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
2. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
3. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
4. Pharmatech 2.0: Introducing Pharmatech Oncology
5. Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
6. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
7. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
8. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
9. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
10. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
11. First Coast Oncology to Offer Next Generation Proton Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):